AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca ultomiris (ravulizumab) — Emerging Markets YoY actual (%) (%)
Form 6-K / 20-F Product Sales Table
Latest, Q2 2026
42.0%
Period ended Jun 30, 2026
Change on a year earlier
-34.0 pts
76.0% in Q2 2025
History
10 quarters
Since Q2 2022
Sources
10
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ultomiris (ravulizumab) — Emerging Markets YoY actual (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 42.0% | -34.0 pts | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 98.0% | +33.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 71.0% | – | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 76.0% | – | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 65.0% | – | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 53.0% | – | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q1 2023 | Mar 31, 2023 | -46.0% | – | Form 6-K FY2023Q1 Earnings Release ↗ |
| Q4 2022 | Dec 31, 2022 | -6.0% | – | Form 6-K FY2022Q4 Earnings Release ↗ |
| Q3 2022 | Sep 30, 2022 | -40.0% | – | Form 6-K FY2022Q3 Earnings Release ↗ |
| Q2 2022 | Jun 30, 2022 | 21.0% | – | Form 6-K FY2022Q2 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Ultomiris (ravulizumab) — Emerging Markets YoY actual (%) (%), quarterly Q2 2022–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_ultomiris_em_act_yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.